| scholarly article | Q13442814 |
| P2093 | author name string | Rando Allikmets | |
| Jian Kong | |||
| Graham Johnson | |||
| Konstantin Petrukhin | |||
| Paul G Pearson | |||
| Boglarka Racz | |||
| Christopher L Cioffi | |||
| Andras Varadi | |||
| P2860 | cites work | Age-related accumulation and spatial distribution of lipofuscin in RPE of normal subjects | Q74114859 |
| Control of rhodopsin activity in vision | Q77421385 | ||
| New Understanding of Age-Related Macular Degeneration Through Quantitative Autofluorescence | Q89353344 | ||
| A photoreceptor cell-specific ATP-binding transporter gene (ABCR) is mutated in recessive Stargardt macular dystrophy | Q24324625 | ||
| Identification and Characterization of a Non-retinoid Ligand for Retinol-binding Protein 4 Which Lowers Serum Retinol-binding Protein 4 Levels in Vivo | Q27653437 | ||
| Systemic complement activation in age-related macular degeneration | Q28285925 | ||
| Phenotype in retinol deficiency due to a hereditary defect in retinol binding protein synthesis | Q28293807 | ||
| Impaired retinal function and vitamin A availability in mice lacking retinol-binding protein | Q28509835 | ||
| Visual Cycle Modulation as an Approach toward Preservation of Retinal Integrity | Q28547211 | ||
| Retinol-binding protein-deficient mice: biochemical basis for impaired vision | Q28586961 | ||
| Preservation of light signaling to the suprachiasmatic nucleus in vitamin A-deficient mice | Q28590718 | ||
| A2E, a byproduct of the visual cycle | Q28609934 | ||
| Reductions in Serum Vitamin A Arrest Accumulation of Toxic Retinal Fluorophores: A Potential Therapy for Treatment of Lipofuscin-Based Retinal Diseases | Q29012269 | ||
| Retinal pigment epithelium defects in humans and mice with mutations in MYO7A: imaging melanosome-specific autofluorescence. | Q30494855 | ||
| Fundus autofluorescence and development of geographic atrophy in age-related macular degeneration. | Q30984629 | ||
| A case of human vitamin A deficiency caused by an inherited defect in retinol-binding protein without clinical symptoms except night blindness | Q33750587 | ||
| RBP4 activates antigen-presenting cells, leading to adipose tissue inflammation and systemic insulin resistance | Q33831780 | ||
| Positively charged retinoids are potent and selective inhibitors of the trans-cis isomerization in the retinoid (visual) cycle | Q33852276 | ||
| Retinoids for treatment of retinal diseases | Q33901076 | ||
| Effects of potent inhibitors of the retinoid cycle on visual function and photoreceptor protection from light damage in mice | Q33931582 | ||
| Inhibition of the visual cycle in vivo by 13-cis retinoic acid protects from light damage and provides a mechanism for night blindness in isotretinoin therapy. | Q33932912 | ||
| The lipofuscin component A2E selectively inhibits phagolysosomal degradation of photoreceptor phospholipid by the retinal pigment epithelium | Q34020740 | ||
| Pharmacological inhibition of lipofuscin accumulation in the retina as a therapeutic strategy for dry AMD treatment | Q34074393 | ||
| Design, synthesis, and evaluation of nonretinoid retinol binding protein 4 antagonists for the potential treatment of atrophic age-related macular degeneration and Stargardt disease | Q34243202 | ||
| Conversion of beta-carotene to retinal pigment | Q34609620 | ||
| Treatment with isotretinoin inhibits lipofuscin accumulation in a mouse model of recessive Stargardt's macular degeneration | Q34960196 | ||
| Complement system dysregulation and inflammation in the retinal pigment epithelium of a mouse model for Stargardt macular degeneration | Q34998079 | ||
| Complement activation by photooxidation products of A2E, a lipofuscin constituent of the retinal pigment epithelium | Q35133725 | ||
| Complement, age-related macular degeneration and a vision of the future | Q35509833 | ||
| Understanding the physiological role of retinol-binding protein in vitamin A metabolism using transgenic and knockout mouse models | Q35571339 | ||
| Stargardt macular dystrophy: common ABCA4 mutations in South Africa--establishment of a rapid genetic test and relating risk to patients | Q35745250 | ||
| Mechanism of all-trans-retinal toxicity with implications for stargardt disease and age-related macular degeneration | Q35762929 | ||
| Lipofuscin and N-retinylidene-N-retinylethanolamine (A2E) accumulate in retinal pigment epithelium in absence of light exposure: their origin is 11-cis-retinal | Q36052545 | ||
| The role of inflammation in the pathogenesis of age-related macular degeneration | Q36405906 | ||
| Retinol-binding protein 4 induces inflammation in human endothelial cells by an NADPH oxidase- and nuclear factor kappa B-dependent and retinol-independent mechanism | Q36435170 | ||
| Primary amines protect against retinal degeneration in mouse models of retinopathies | Q36455469 | ||
| A1120, a nonretinoid RBP4 antagonist, inhibits formation of cytotoxic bisretinoids in the animal model of enhanced retinal lipofuscinogenesis | Q36530609 | ||
| Diseases caused by defects in the visual cycle: retinoids as potential therapeutic agents | Q36591612 | ||
| New therapeutic targets in atrophic age-related macular degeneration | Q36804427 | ||
| The age lipid A2E and mitochondrial dysfunction synergistically impair phagocytosis by retinal pigment epithelial cells | Q36861483 | ||
| Bicyclic [3.3.0]-Octahydrocyclopenta[c]pyrrolo Antagonists of Retinol Binding Protein 4: Potential Treatment of Atrophic Age-Related Macular Degeneration and Stargardt Disease | Q36992465 | ||
| Complement activation by bisretinoid constituents of RPE lipofuscin | Q37158928 | ||
| Rpe65 Leu450Met variant is associated with reduced levels of the retinal pigment epithelium lipofuscin fluorophores A2E and iso-A2E. | Q37415751 | ||
| Natural history of phenotypic changes in Stargardt macular dystrophy | Q37448421 | ||
| Hemangiosarcoma in rodents: mode-of-action evaluation and human relevance | Q37518959 | ||
| The role of the complement system in age-related macular degeneration | Q37646779 | ||
| Bisretinoid-mediated complement activation on retinal pigment epithelial cells is dependent on complement factor H haplotype | Q37691648 | ||
| RBP4: a controversial adipokine | Q37915836 | ||
| Genotyping microarray (gene chip) for the ABCR (ABCA4) gene. | Q38349817 | ||
| Complement Component C5a Primes Retinal Pigment Epithelial Cells for Inflammasome Activation by Lipofuscin-mediated Photooxidative Damage | Q38819720 | ||
| N-(4-hydroxyphenyl)retinamide induces apoptosis in human retinal pigment epithelial cells: retinoic acid receptors regulate apoptosis, reactive oxygen species generation, and the expression of heme oxygenase-1 and Gadd153. | Q40232126 | ||
| beta-Carotene conversion into vitamin A in human retinal pigment epithelial cells | Q40368582 | ||
| Histopathology and immunocytochemistry of the neurosensory retina in fundus flavimaculatus. | Q40674593 | ||
| A2E, a lipofuscin fluorophore, in human retinal pigmented epithelial cells in culture. | Q40919605 | ||
| Lipofuscin of the retinal pigment epithelium: a review | Q41145720 | ||
| Small molecule RPE65 antagonists limit the visual cycle and prevent lipofuscin formation | Q42164095 | ||
| Understanding RPE lipofuscin | Q42904619 | ||
| Retinol transport and metabolism in transthyretin-"knockout" mice. | Q44121107 | ||
| Dephosphorylation by protein phosphatase 2A regulates visual pigment regeneration and the dark adaptation of mammalian photoreceptors. | Q45071188 | ||
| Investigation of oral fenretinide for treatment of geographic atrophy in age-related macular degeneration | Q46663923 | ||
| Hyperlipofuscinosis and subretinal fibrosis in Stargardt's disease. | Q49107580 | ||
| The lipofuscin fluorophore A2E mediates blue light-induced damage to retinal pigmented epithelial cells. | Q50511473 | ||
| Cell loss in the aging retina. Relationship to lipofuscin accumulation and macular degeneration. | Q52525243 | ||
| Retinal age pigments generated by self-assembling lysosomotropic detergents | Q59071585 | ||
| In vitro interaction of fenretinide with plasma retinol-binding protein and its functional consequences | Q67546270 | ||
| Teratogenicity of N-(4-hydroxyphenyl)-all-trans-retinamide in rats and rabbits | Q69918949 | ||
| Aging human RPE: morphometric analysis of macular, equatorial, and peripheral cells | Q71275163 | ||
| Retinal pigment epithelial abnormalities in fundus flavimaculatus: a light and electron microscopic study | Q72637349 | ||
| N-(4-hydroxyphenyl)retinamide (fenretinide) induces retinol-binding protein secretion from liver and accumulation in the kidneys in rats | Q72901738 | ||
| Fundus autofluorescence in age-related macular disease imaged with a laser scanning ophthalmoscope | Q73089239 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 29 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Stargardt disease | Q1317319 |
| P304 | page(s) | 11574-11588 | |
| P577 | publication date | 2018-06-05 | |
| P1433 | published in | Journal of Biological Chemistry | Q867727 |
| P1476 | title | A non-retinoid antagonist of retinol-binding protein 4 rescues phenotype in a model of Stargardt disease without inhibiting the visual cycle | |
| P478 | volume | 293 |
| Q92915328 | Comparative pharmacokinetics and pharmacodynamics of the advanced Retinol-Binding Protein 4 antagonist in dog and cynomolgus monkey |
| Q100455024 | Deep learning segmentation of hyperautofluorescent fleck lesions in Stargardt disease |
| Q91954772 | Design, Synthesis, and Preclinical Efficacy of Novel Nonretinoid Antagonists of Retinol-Binding Protein 4 in the Mouse Model of Hepatic Steatosis |
| Q89521005 | RBP3: a possible prognostic marker and therapeutic target in diabetic retinopathy |
Search more.